Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company whose news flow centers on the development, validation, and commercialization of nucleosome-based blood tests for human and veterinary medicine. Company updates frequently highlight progress across its Nu.Q® platform, including cancer-focused assays, NETosis-related biomarkers, and companion animal diagnostics.
Readers of this VNRX news page can expect coverage of clinical study results, technology milestones, and collaborations. Recent announcements have described breakthrough clinical data for the Nu.Q® Vet Feline assay in detecting lymphoma in cats, positioning it as a potential simple, affordable blood-based liquid biopsy test for feline cancer. Other news has detailed the first commercial sale of Nu.Q® Cancer assays to a major European cancer center for internal certification ahead of routine clinical use in lung cancer management.
VolitionRx also issues news on its role in sepsis and NETosis research. The company has reported inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government-backed real-world program evaluating early detection of sepsis, and has highlighted broader work on NETs biomarkers and point-of-care nucleosome testing. Additional updates cover scientific advances such as its Capture-Seq™ method for enriching ultrashort transcription factor-bound DNA fragments in plasma, which the company positions as a potential foundation for accurate, lower-cost liquid biopsy tests.
Investors and followers will also find announcements on business reviews, licensing and co-marketing agreements with diagnostic companies, capital-raising transactions, and veterinary initiatives such as donations of Nu.Q® Vet Cancer Tests to crisis response dogs. This page aggregates these developments so that readers can track how VolitionRx’s clinical, commercial, and financial activities evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
VolitionRx Limited (NYSE AMERICAN: VNRX) is set to host a Capital Markets Day on May 11, 2023, at 2 p.m. Eastern Time, in a hybrid format at the New York Stock Exchange and via live webcast. The event will feature presentations by the executive team and recognized experts in the field, including Dr. Andy Retter and veterinary oncologists Professor Heather Wilson-Robles and Dr. Sue Ettinger. Topics will include the company's corporate strategy, Nu.Q® technology applications in sepsis, and veterinary diagnostics. A Q&A session will follow the presentations. Interested attendees can register for the event virtually or contact for in-person attendance. The event will also be webcasted, with presentations available on Volition's website post-event. VolitionRx focuses on cost-effective blood tests for diagnosing and monitoring diseases like cancer.
VolitionRx Limited (NYSE AMERICAN: VNRX) reported its full fiscal year 2022 results, highlighting a 240% revenue increase to approximately $300,000. The company secured global licensing agreements with Heska Corporation and IDEXX Laboratories for its Nu.Q® Vet Cancer Test, generating an upfront payment of $10 million and potential milestone payments up to $18 million. Cash and equivalents stood at $10.9 million as of December 31, 2022, after raising $8 million through a public offering. Volition continues to expand its intellectual property portfolio, holding 34 patent families and 97 granted patents. A conference call is scheduled for March 16, 2023, to discuss the results.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
